Expense Reimbursement Waiver Agreement Sample Contracts

AMENDMENT NO. 2 TO EXPENSE REIMBURSEMENT WAIVER AGREEMENT

Expense Reimbursement Waiver Agreement • April 19th, 2018 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York

• Contract Type
  Expense Reimbursement Waiver Agreement
• Filed
  April 19th, 2018
• Company
  Rosetta Genomics Ltd.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This AMENDMENT NO. 2, dated as of April 17, 2018 (“Amendment No. 2”), to the Expense Reimbursement Waiver Agreement (as amended, the “Agreement”), dated as of February 27, 2018, by and between Rosetta Genomics Ltd., an Israeli corporation with a principal place of business at 10 Plaut Street, Science Park, Rehovot 76706, Israel (the “Company”) and Genoptix, Inc., a Delaware corporation with a principal place of business at 2131 Faraday Avenue, Carlsbad, California 92008 (“Parent”), is entered into by and between the Company and Parent. Capitalized terms used in this Amendment No. 2 and not otherwise defined herein shall have the meanings set forth in the Agreement.

EXPENSE REIMBURSEMENT WAIVER AGREEMENT

Expense Reimbursement Waiver Agreement • March 13th, 2018 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York

• Contract Type
  Expense Reimbursement Waiver Agreement
• Filed
  March 13th, 2018
• Company
  Rosetta Genomics Ltd.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This EXPENSE REIMBURSEMENT WAIVER AGREEMENT (this “Agreement”) is made and entered into as of February 27, 2018, by and between Genoptix, Inc., a Delaware corporation (“Parent”), and Rosetta Genomics Ltd. (the “Company”).

AMENDMENT NO. 1 TO EXPENSE REIMBURSEMENT WAIVER AGREEMENT

Expense Reimbursement Waiver Agreement • March 13th, 2018 • Rosetta Genomics Ltd. • Pharmaceutical preparations • New York

• Contract Type
  Expense Reimbursement Waiver Agreement
• Filed
  March 13th, 2018
• Company
  Rosetta Genomics Ltd.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This AMENDMENT NO. 1, dated as of March 11, 2018 (“Amendment No. 1”), to the Expense Reimbursement Waiver Agreement (the “Agreement”), dated as of February 27, 2018, by and between Rosetta Genomics Ltd., an Israeli corporation with a principal place of business at 10 Plaut Street, Science Park, Rehovot 76706, Israel (the “Company”) and Genoptix, Inc., a Delaware corporation with a principal place of business at 2131 Faraday Avenue, Carlsbad, California 92008 (“Parent”), is entered into by and between the Company and Parent. Capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the meanings set forth in the Agreement.